| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5594296 | American Heart Journal | 2017 | 21 Pages |
Abstract
Given the small number of events in ENSURE-AF, no effect of renal (dys)function was demonstrated in comparing edoxaban to enoxaparin-warfarin for cardioversion; efficacy and safety of edoxaban remained consistent even in patients with normal or supranormal renal function.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Gregory Y.H. Lip, Naab Al-Saady, Michael D. Ezekowitz, Maciej Banach, Andreas Goette,